Skip to main content
Clinical Trials/NCT00982514
NCT00982514UnknownNot Applicable

Thromboembolic Complications Related to Asparaginase in Children With ALL Treated According to NOPHO ALL 2008

Oslo University Hospital1 site in 1 country60 target enrollmentStarted: September 2009Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
60
Locations
1
Primary Endpoint
Clinical evident thrombosis

Study Overview

Brief Summary

The study will examine the prevalence of venous thromboembolism in children with acute lymphoblastic leukaemia treated in accordance with NOPHO ALL-2008. The investigators will prospectively study clinical symptomatic thromboses, asymptomatic central line-associated thromboses, and infections.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
1 Year to 16 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Acute lymphoblastic leukaemia,
  • Age 1 year to 16 years old,
  • Central line,
  • Protocol NOPHO ALL 2008.

Exclusion Criteria

  • Refusal of participation,
  • Treated according to protocol other than NOPHO ALL 2008.

Outcomes

Primary Outcomes

Clinical evident thrombosis

Time Frame: 33 weeks

Asymptomatic central line-associated thrombosis

Time Frame: 33 weeks

Secondary Outcomes

  • Positive blood culture(33 weeks)

Investigators

Sponsor
Oslo University Hospital
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials